Sandoz, a Novartis (NYSE:NVS) division, announces the US retail launch of SYMJEPI (epinephrine) 0.3 mg and 0.15 mg Injections. It will be now available in local pharmacies across the nation.
SYMJEPI is a single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, a severe reaction that can lead to death if left untreated.
Sandoz launched SYMJEPI 0.3 mg Injection in the institutional (hospital) setting earlier this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.